Publication: Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: A multicenter study
Issued Date
2018-08-25
Resource Type
ISSN
14712261
Other identifier(s)
2-s2.0-85052612194
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Cardiovascular Disorders. Vol.18, No.1 (2018)
Suggested Citation
Rungroj Krittayaphong, Arjbordin Winijkul, Komsing Methavigul, Wattana Wongtheptien, Chaiyasith Wongvipaporn, Treechada Wisaratapong, Rapeephon Kunjara-Na-Ayudhya, Smonporn Boonyaratvej, Chulalak Komoltri, Pontawee Kaewcomdee, Ahthit Yindeengam, Piyamitr Sritara Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: A multicenter study. BMC Cardiovascular Disorders. Vol.18, No.1 (2018). doi:10.1186/s12872-018-0911-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46427
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: A multicenter study
Other Contributor(s)
Chulalongkorn University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkia University
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Vichaiyut Hospital
Central Chest Institute of Thailand
Chiangrai Prachanukroh Hospital
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkia University
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Faculty of Medicine, Siriraj Hospital, Mahidol University
Vichaiyut Hospital
Central Chest Institute of Thailand
Chiangrai Prachanukroh Hospital
Abstract
© 2018 The Author(s). Background: Anticoagulation therapy is a standard treatment for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) that have risk factors for stroke. However, anticoagulant increases the risk of bleeding, especially in Asians. We aimed to investigate the risk profiles and pattern of antithrombotic use in patients with NVAF in Thailand, and to study the reasons for not using warfarin in this patient population. Methods: A nationwide multicenter registry of patients with NVAF was created that included data from 24 hospitals located across Thailand. Demographic data, atrial fibrillation-related data, comorbid conditions, use of antithrombotic drugs, and reasons for not using warfarin were collected. Data were recorded in a case record form and then transferred into a web-based system. Results: A total of 3218 patients were included. Average age was 67.3 ± 11.3 years, and 58.2% were male. Average CHADS 2 , CHA 2 DS 2 -VASc, and HAS-BLED score was 1.8 ± 1.3, 3.0 ± 1.7, and 1.5 ± 1.0, respectively. Antiplatelet was used in 26.5% of patients, whereas anticoagulant was used in 75.3%. The main reasons for not using warfarin in those with CHA 2 DS 2 -VASc ≥2 included already taking antiplatelet (26.6%), patient preference (23.1%), and using non-vitamin K antagonist oral anticoagulants (NOACs) (22.7%). Anticoagulant was used in 32.3% of CHA 2 DS 2 -VASc 0, 56.8% of CHA 2 DS 2 -VASc 1, and 81.6% of CHA 2 DS 2 -VASc ≥2. The use of NOACs increased from 1.9% in 2014 to 25.6% in 2017. Conclusions: Anticoagulation therapy was prescribed in 75.3% of patients with NVAF. Among those receiving anticoagulant, 90.9% used warfarin and 9.1% used NOACs. The use of NOACs increased over time.